Meeting
2024 ASCO Annual Meeting
Comparison of outcomes with docetaxel or ARPI combination therapy for metastatic hormone-sensitive prostate cancer (mHSPC) by volume of disease.
Presenter
Martin W. Schoen, MD, MPH
Saint Louis University School of Medicine
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer– Advanced/Hormone-Sensitive
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 5092)
DOI
10.1200/JCO.2024.42.16_suppl.5092
Abstract #
5092
Poster Bd #
498
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2023 ASCO Genitourinary Cancers Symposium
Dosing, safety, and pharmacokinetics (PK) of combination therapy with darolutamide (DARO), androgen-deprivation therapy (ADT), and docetaxel (DOC) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) in the ARASENS study.
Speaker: Arash Rezazadeh, MD
Videos & Slides
2023 ASCO Genitourinary Cancers Symposium
Rucaparib for metastatic castration-resistant prostate cancer (mCRPC): TRITON3 interim overall survival and efficacy of rucaparib vs docetaxel or second-generation androgen pathway inhibitor therapy.
Speaker: Alan Haruo Bryce, MD
Videos & Slides
2022 ASCO Genitourinary Cancers Symposium
Overall survival with darolutamide versus placebo in combination with androgen-deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer in the phase 3 ARASENS trial.
Speaker: Matthew Raymond Smith, PhD, MD
Videos & Slides
2022 ASCO Genitourinary Cancers Symposium
PSMAddition: A phase 3 trial to compare treatment with 177Lu-PSMA-617 plus standard of care (SOC) versus SOC alone in patients with metastatic hormone-sensitive prostate cancer.
Speaker: A. Oliver Sartor, MD